1. Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. (19th August 2018) Authors: Fogelman, David; Cubillo, Antonio; García‐Alfonso, Pilar; Mirón, María Luisa Limón; Nemunaitis, John; Flora, Daniel; Borg, Christophe; Mineur, Laurent; Vieitez, Jose M.; Cohn, Allen; Saylors, Gene; Assad, Albert; Switzky, Julie; Zhou, Li; Bendell, Johanna Journal: Cancer medicine Issue: Volume 7:Number 11(2018:Nov.) Page Start: 5382 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗